New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
19:03 EDTARWR, HAIN, OCLR, IDRA, CHRW, AGEN, IDIX, MMM, GNW, MYGNOn The Fly: After Hours Movers
UP AFTER EARNINGS: Myriad Genetics (MYGN), up 14.5%... Genworth (GNW), up 5%... Oclaro (OCLR), up 5.6%. ALSO HIGHER: 3M (MMM), up 2% after the Dow member announced a $12B share repurchase plan... Idenix Pharmaceuticals (IDIX), up 7.3% after investment firm Baupost Group raised its stake in the company to more than 35% from roughly 27% and disclosed it was granted observer rights for meetings of Idenix's board and committees. DOWN AFTER EARNINGS: C.H. Robinson (CHRW), down 6.4%... Hain Celestial (HAIN), down 7.9%. ALSO LOWER: Agenus (AGEN), down 6.2% after announcing a public offering of common stock... Idera Pharmaceuticals (IDRA), down 3.8% after filing to sell common stock and warrants... Arrowhead Research (ARWR), down 3% after reporting a larger-than-expected quarterly loss and filing a $200M mixed securities shelf.
News For MMM;MYGN;GNW;OCLR;IDIX;CHRW;HAIN;AGEN;IDRA;ARWR From The Last 14 Days
Check below for free stories on MMM;MYGN;GNW;OCLR;IDIX;CHRW;HAIN;AGEN;IDRA;ARWR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 11, 2014
07:53 EDTCHRWC.H. Robinson upgraded to Buy from Hold at BB&T
April 10, 2014
09:20 EDTCHRWC.H. Robinson margins improving, says Cleveland Research
Cleveland Research's checks indicate C.H. Robinson's margins have improved due to increased volumes of spot/transactional freight and shippers accepting rate increases. The firm remains slightly below consensus for Q1 earnings estimates and slightly above consensus for Q2.
April 9, 2014
16:39 EDTARWRPoint72 boosts stake in Arrowhead Research to 7.1% from 5.2%
Subscribe for More Information
07:23 EDTIDIXEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
April 8, 2014
16:39 EDTARWRIntegrated Core Strategies reports 4.9% passive stake in Arrowhead Research
11:47 EDTIDIXIdenix price target raised to $9 from $6 at Leerink
Leerink raised Idenix's price target to $9 from $6 citing positive IDX21437 data.
April 7, 2014
16:34 EDTMYGNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information
16:28 EDTIDIXOn The Fly: Closing Wrap
Subscribe for More Information
16:13 EDTIDRAIdera says preclinical data shows inhibition of lymphoma cells
Idera Pharmaceuticals presented new preclinical data demonstrating the ability of its Toll-like receptor antagonist, IMO-8400, to inhibit the survival and proliferation of B-cell lymphoma cells harboring the oncogenic MYD88 L265P genetic mutation. These data add to the research which supports the company’s efforts to develop IMO-8400 for the treatment of genetically defined forms of B-cell lymphoma. The data build upon reports from independent investigators and provide additional evidence that the MYD88 L265P mutation, which is present in certain B-cell lymphomas, results in over-activation of TLR7 and TLR9 mediated signaling. Idera has opened enrollment in a Phase 1/2 trial of IMO-8400 designed to evaluate IMO-8400’s safety, tolerability and potential clinical activity in patients with Waldenstrom’s macroglobulinemia who are refractory to prior therapies. The company anticipates that patient treatment in this trial will begin in Q2. Idera has also submitted a separate protocol to the U.S. FDA to conduct a Phase 1/2 trial in patients with DLBCL who harbor the MYD88 L265P mutation.
13:31 EDTIDIXIdenix risk/reward remains favorable, says UBS
UBS said Idenix's IDX21437 update this morning supports its favorable risk/reward thesis. Shares are Buy rated with an $11 price target.
11:09 EDTMYGNMyriad Genetics advises prior BRACAnalysis news release be disregarded
Myriad Genetics advised that readers should disregard the news release, "Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis" issued April 7 by the company over GlobeNewswire.
10:16 EDTMYGNMyriad Genetics has a conference call hosted by JPMorgan
Subscribe for More Information
07:15 EDTIDIXIdenix announces promising clinical data, continued progress in HCV programs
Idenix Pharmaceuticals announced continued progress of the Company's program to develop nucleotide prodrug inhibitors for the treatment of hepatitis C virus, or HCV, infection. Idenix is reporting potent antiviral activity of mean maximum 4.2-4.3 log10 IU/mL reductions for patients infected with HCV genotype 1, 2 or 3 receiving 300 mg once daily of IDX21437 in the seven-day proof-of-concept portion of a phase I/II clinical trial. Based on this progress, the Company's goal is to initiate a combination clinical trial of IDX21437 and samatasvir, a pan-genotypic NS5A inhibitor, in mid-2014. In addition, Idenix has selected a follow-on uridine-based nucleotide prodrug, IDX21459, from its ongoing nucleotide discovery program and initiated enrollment for the healthy volunteer portion of a phase I clinical trial. In January, Idenix initiated the seven-day proof-of-concept portion of a phase I/II clinical trial for IDX21437. The trial completed enrollment of 44 treatment-naïve, genotype, or GT, 1, 2 or 3 HCV-infected patients. Patients were randomized to receive once-daily doses of placebo, 50 mg, 150 mg, or 300 mg of IDX21437 for seven days. In April 2014, Idenix initiated enrollment for the healthy volunteer portion of a phase I clinical trial of IDX21459 in Europe. This portion of the study is expected to enroll approximately 50 healthy volunteers and will evaluate once-daily doses of IDX21459 ranging from 10 mg – 300 mg. The proof-of-concept portion of the study is expected to enroll a total of 40 treatment-naïve, genotype 1 HCV-infected patients who will receive once-daily doses of placebo, 50 - 300 mg of IDX21459 for seven days. IDX21459 has shown a favorable preclinical profile including potent, pan-genotypic activity and favorable safety with respect to cardiac, mitochondrial and genotoxicity assessments.
05:48 EDTMYGNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information
April 4, 2014
11:07 EDTMYGNMyriad Genetics price target raised to $42 from $34 at Piper Jaffray
Piper Jaffray raised its price target for Myriad Genetics shares to $42 to reflect CMS' recent decision to increase BRCA reimbursement. The firm keeps an Overweight rating on the stock.
10:02 EDTMYGNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:48 EDTMYGNMyriad Genetics upgraded to Buy from Neutral at Mizuho
Subscribe for More Information
06:46 EDTMYGNMyriad Genetics upgraded to Buy from Neutral at Mizuho
April 3, 2014
17:49 EDTHAINHain Celestial CEO: Food prices going up, seeking 2%-3% price hikes
Subscribe for More Information
07:37 EDTMYGNMyriad Genetics price target raised to $40 from $28 at Mizuho
Mizuho raised Myriad's price target to $40 from $28 following the better than expected CMS pricing for BRCA testing. Shares are Neutral rated.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use